Abstract
Treatment options are limited for patients (pts) with high-risk non-muscle-invasive bladder cancer (HR-NMIBC) unresponsive to intravesical bacillus Calmette–Guérin (BCG). TAR-200 is an intravesical drug-delivery system which provides local continuous release of gemcitabine within the bladder. This study will assess rate of complete response (CR) upon treatment with TAR-200 + systemic CET (anti–PD-1 antibody), TAR-200, and CET in BCG-unresponsive pts with HR-NMIBC ineligible for or who decline radical cystectomy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.